Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacia North America Rx President Is Spiers; Hassan Adds Chairman Title

Executive Summary

Pharmacia North American Pharmaceuticals President Mark Spiers will lead the company's search for a new head of U.S. sales.

You may also be interested in...



Merck Cozaar profit sharing

Dupont will receive 50% of Cozaar operating profits in North America starting Feb. 1, Merck Investor Relations Senior Director Laura Jordan announces Jan. 23. Existing Dupont royalties on Merck's losartan products Cozaar and Hyzaar will remain unchanged. Dupont receives 10% of profits from sales of the hypertension products. The profit sharing will give Dupont its largest source of revenue as the chemical company moves forward with plans to spin off the Rx business. Cozaar/Hyzaar revenues in the U.S. totaled $770 mil. in 2000

Novartis U.S. Rx Marketing Head Schofield Joins From Pharmacia

Novartis' efforts to reinvigorate its U.S. pharmaceuticals business in 2001 will be led by former Pharmacia VP-U.S. Sales Greg Schofield.

DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears

DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel